Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that KRAS p.G12C status confers therapeutic sensitivity to Sotorasib in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Canada:
LUMAKRAS (sotorasib) is indicated for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.